Novartis' Sandoz: Between Generics and Pharma
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Collection: HBSP (USA)
Ref: HBS-114033-E
Format: PDF
Number of pages: 24
Publication Date: Mar 10, 2014
Language: English
Description
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Read more
Year: 2014
Industry Setting: Pharmaceuticals
Leave your rating
"Novartis' Sandoz: Between Generics and Pharma"
Register for free with IESE Publishing and enjoy all the advantages
What type of account do you want to create?
Choose account type
Professors
Academic Institutions
Companies
Individuals